aTYR PHARMA INC - COMMON STOCK (ATYR) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
ATYR on Nasdaq
Shares outstanding
97,996,626
Price per share
$0.89
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
53,787,796
Total reported value
$42,119,016
% of total 13F portfolios
0%
Share change
-7,072,781
Value change
-$5,233,279
Number of holders
82
Price from insider filings
$0.89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of aTYR PHARMA INC - COMMON STOCK (ATYR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FEDERATED HERMES, INC. 11% -39% $55,463,739 -$21,682,577 10,544,437 -28% Federated Hermes, Inc. 30 Sep 2025
BlackRock, Inc. 6.5% $29,221,482 5,763,606 BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 5.2% $23,601,093 4,655,048 The Vanguard Group 30 Jun 2025
Point72 Asset Management, L.P. 3.2% $9,617,297 2,845,354 Point72 Asset Management, L.P. 31 Mar 2025

As of 31 Dec 2025, 82 institutional investors reported holding 53,787,796 shares of aTYR PHARMA INC - COMMON STOCK (ATYR). This represents 55% of the company’s total 97,996,626 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of aTYR PHARMA INC - COMMON STOCK (ATYR) together control 53% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 14,697,995 0% 0% $11,510,000
FEDERATED HERMES, INC. 11% 10,509,678 -0.33% 0.01% $8,230,129
BlackRock, Inc. 6.7% 6,549,699 +1.2% 0% $5,129,068
VANGUARD GROUP INC 5.1% 4,961,871 -12% 0% $3,885,145
GSA CAPITAL PARTNERS LLP 2.7% 2,630,638 +272% 0.18% $2,060,000
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,283,717 +4.8% 0% $1,788,716
STATE STREET CORP 1.8% 1,724,843 -59% 0% $1,350,725
UBS Group AG 1.7% 1,625,297 -64% 0% $1,272,607
MORGAN STANLEY 1.4% 1,403,009 +98% 0% $1,098,696
TWO SIGMA ADVISERS, LP 0.86% 841,350 0% $658,861
AQR CAPITAL MANAGEMENT LLC 0.79% 769,820 0% $602,847
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.78% 764,743 +504% 0% $598,870
NORTHERN TRUST CORP 0.72% 702,186 +4.2% 0% $549,882
Tikvah Management LLC 0.47% 460,833 0% 0.1% $360,878
TWO SIGMA INVESTMENTS, LP 0.46% 454,443 +115% 0% $355,874
GOLDMAN SACHS GROUP INC 0.35% 345,587 -50% 0% $270,629
Nuveen, LLC 0.23% 227,941 0% 0% $178,500
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.23% 221,767 -15% 0% $173,666
Bank of New York Mellon Corp 0.2% 193,532 -3.1% 0% $151,555
GROUP ONE TRADING LLC 0.19% 191,048 +1008% 0% $149,610
JANE STREET GROUP, LLC 0.19% 188,149 -17% 0% $147,339
VICTORY CAPITAL MANAGEMENT INC 0.19% 181,966 -5.6% 0% $142,498
BARCLAYS PLC 0.18% 174,182 -49% 0% $136,402
BANK OF AMERICA CORP /DE/ 0.13% 126,700 -29% 0% $99,206
DEUTSCHE BANK AG\ 0.12% 120,341 +3779% 0% $93,866

Institutional Holders of aTYR PHARMA INC - COMMON STOCK (ATYR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 53,787,796 $42,119,016 -$5,233,279 $0.78 82
2025 Q3 60,897,995 $43,933,118 -$49,470,950 $0.72 99
2025 Q2 66,359,568 $336,444,770 +$26,875,848 $5.07 109
2025 Q1 61,756,683 $186,507,450 +$18,904,946 $3.02 86
2024 Q4 54,865,656 $198,612,160 +$28,523,986 $3.62 77
2024 Q3 47,869,886 $84,250,295 -$378,413 $1.76 55
2024 Q2 48,121,584 $75,070,910 +$8,935,546 $1.56 44
2024 Q1 41,805,838 $81,517,658 +$1,482,921 $1.95 56
2023 Q4 41,229,482 $58,129,683 +$3,571,040 $1.41 46
2023 Q3 37,134,381 $58,673,004 +$2,049,031 $1.58 41
2023 Q2 35,668,257 $77,043,513 +$2,315,570 $2.16 41
2023 Q1 34,663,995 $72,793,910 +$35,335,611 $2.10 37
2022 Q4 18,353,420 $40,193,707 -$2,084,056 $2.19 36
2022 Q3 19,059,787 $57,179,570 +$782,338 $3.00 33
2022 Q2 18,767,627 $53,115,149 -$3,104,794 $2.83 34
2022 Q1 19,627,641 $105,009,778 -$6,312,765 $5.35 39
2021 Q4 20,554,611 $153,544,033 +$11,326,984 $7.47 46
2021 Q3 233,068 $2,114,000 -$353,397 $7.26 4
2021 Q2 6,787,129 $33,117,000 +$4,918,998 $4.88 23
2021 Q1 5,779,531 $25,721,000 +$251,380 $4.45 19
2020 Q4 5,763,402 $22,361,000 -$366,396 $3.88 19
2020 Q3 5,634,598 $18,198,000 +$467,508 $3.23 20
2020 Q2 5,472,169 $24,295,000 +$1,598,388 $4.44 21
2020 Q1 5,114,483 $14,319,000 +$9,326,688 $2.80 21
2019 Q4 1,793,570 $7,478,000 +$294,915 $4.17 13
2019 Q3 1,727,317 $6,046,000 +$4,183,916 $3.50 15
2019 Q2 530,377 $193,000 +$193,000 $0.36 5